Rocket Pharmaceuticals, Inc. (RCKT) financial statements (2023 and earlier)

Company profile

Business Address 350 FIFTH AVENUE
NEW YORK, NY 10118
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
Q4
9/30/2021
Q3
6/30/2021
Q2
3/31/2021
Q1
12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:388,700421,500426,800466,400482,700228,700249,800
Cash and cash equivalents232,694245,644264,608252,540297,09882,226163,203
Short-term investments156,046175,815162,222213,813185,621146,46486,600
Other undisclosed cash, cash equivalents, and short-term investments(40)41(30)47(19)10(3)
Other undisclosed current assets3,3593,5693,6265,4224,6454,5145,636
Total current assets:392,059425,069430,426471,822487,345233,214255,436
Noncurrent Assets
Finance lease, right-of-use asset48,48049,01149,50750,31150,52152,54749,250
Operating lease, right-of-use asset1,5691,4671,6281,7879141,0941,270
Property, plant and equipment22,29922,09020,98919,83319,20615,80314,314
Intangible assets, net (including goodwill)30,81530,81530,81530,81530,81530,81530,815
Goodwill30,81530,81530,81530,81530,81530,81530,815
Deposits noncurrent assets455455455455455455455
Restricted cash and investments1,3431,3341,3341,4611,5681,5681,525
Total noncurrent assets:104,961105,172104,728104,662103,479102,28297,629
TOTAL ASSETS:497,020530,241535,154576,484590,824335,496353,065
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:19,61522,00817,88433,16825,47224,83018,245
Accounts payable7251,1061,2723371,4565,6273,958
Accrued liabilities1,6781,8471,4042,2872,1671,4391,099
Employee-related liabilities4,5333,8153,1156,1874,8752,7962,072
Interest and dividends payable  1234491,1226201,252
Other undisclosed accounts payable and accrued liabilities12,67915,24011,97023,90815,85214,3489,864
Debt1,6891,6776,7686,6416,5196,3971,621
Other undisclosed current liabilities863804792683626728819
Total current liabilities:22,16724,48925,44440,49232,61731,95520,685
Noncurrent Liabilities
Long-term debt and lease obligation20,04920,00020,16655,87154,55261,67765,834
Long-term debt, excluding current maturities   35,54435,06642,13246,228
Finance lease, liability19,14419,10919,07019,02818,98818,94618,900
Operating lease, liability9058911,0961,299498599706
Liabilities, other than long-term debt80941071221362323
Other liabilities80941071221362323
Total noncurrent liabilities:20,12920,09420,27355,99354,68861,70065,857
Total liabilities:42,29644,58345,71796,48587,30593,65586,542
Stockholders' equity
Stockholders' equity attributable to parent454,724485,658489,437479,999503,519241,841266,523
Common stock645644634619610552551
Treasury stock, value     (76) 
Additional paid in capital946,152932,776886,431842,477825,794503,223498,590
Accumulated other comprehensive income (loss)(161)(97)(81)(75)(42)69229
Accumulated deficit(491,912)(447,665)(397,547)(363,022)(322,843)(261,927)(232,847)
Total stockholders' equity:454,724485,658489,437479,999503,519241,841266,523
TOTAL LIABILITIES AND EQUITY:497,020530,241535,154576,484590,824335,496353,065

Income statement (P&L) ($ in thousands)

12/31/2021
Q4
9/30/2021
Q3
6/30/2021
Q2
3/31/2021
Q1
12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
Gross profit:(400)(200)(300)    
Operating expenses(44,333)(49,646)(34,048)(39,222)(59,238)(27,387)(23,559)
Other undisclosed operating income400200300    
Operating loss:(44,333)(49,646)(34,048)(39,222)(59,238)(27,387)(23,559)
Interest and debt expense(463)(534)(251)(1,729)(1,641)(1,967)(1,786)
Net loss:(44,796)(50,180)(34,299)(40,951)(60,879)(29,354)(25,345)
Other undisclosed net income (loss) attributable to parent54962(226)772(37)274305
Net loss available to common stockholders, diluted:(44,247)(50,118)(34,525)(40,179)(60,916)(29,080)(25,040)

Comprehensive Income ($ in thousands)

12/31/2021
Q4
9/30/2021
Q3
6/30/2021
Q2
3/31/2021
Q1
12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
Net loss:(44,796)(50,180)(34,299)(40,951)(60,879)(29,354)(25,345)
Comprehensive loss:(44,796)(50,180)(34,299)(40,951)(60,879)(29,354)(25,345)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent48546(232)739(148)114609
Comprehensive loss, net of tax, attributable to parent:(44,311)(50,134)(34,531)(40,212)(61,027)(29,240)(24,736)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: